nach oben

Drugs

Erschienen in:

01.10.2004 | Adis Drug Profile

Lumiracoxib

verfasst von: Katherine A. Lyseng-Williamson, Monique P. Curran

Erschienen in: Drugs | Ausgabe 19/2004

Einloggen, um Zugang zu erhalten

Abstract

▲ Lumiracoxib is a highly selective and potent cyclo-oxygenase (COX)-2 inhibitor, with a novel structure that conveys weakly acidic properties and a unique pharmacological profile. It is rapidly absorbed, with a relatively short plasma half-life.
▲ In well designed clinical trials of 1–52 weeks’ duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100–400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily.
▲ In single- and multiple-dose well designed trials in patients with acute pain associated with primary dysmenorrhoea, dental or orthopaedic surgery or tension-type headache, lumiracoxib 100–800mg once daily was more effective in relieving acute pain than placebo or controlled-release oxycodone 20mg, and was at least as effective as selective COX-2 inhibitors or nonselective NSAIDs.
▲ Lumiracoxib was generally well tolerated in clinical trials, with a similar overall tolerability profile to those of placebo and other COX-2-selective inhibitors.
▲ In a large 52-week safety trial in patients with OA, lumiracoxib 400mg once daily had a rate of gastrointestinal ulcer complications that was approximately one-third to one-quarter of that of ibuprofen 800mg three times daily or naproxen 500mg twice daily. Lumiracoxib was not associated with an increasein cardiovascular events.

The use of trade names is for product identification purposes only and does not imply endorsement.

Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003; 63(1): 33–45PubMedCrossRef

Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004; 33(1): 1–6PubMedCrossRef

Marshall PJ, Berry C, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 [abstract no. SAT0013]. Ann Rheum Dis 2002; 61 Suppl. 1: 259. Plus poster presented at the Annual European Congress of Rheumatology; 2002 Jun 12–15; Stockholm

Scott G, Rordorf C, Blood P, et al. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects [abstract no. FRI0300]. Ann Rheum Dis 2002; 61 Suppl. 1: 242. Plus poster presented at the Annual European Congress of Rheumatology; 2002 Jun 12–15; StockholmCrossRef

Rordorf C, Scott G, Milosavljev S, et al. Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX189 in healthy subjects [abstract no. AB0284]. Ann Rheum Dis 2002; 61 Suppl. 1: 420

Hartmann S, Scott G, Rordorf C, et al. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects [abstract no. P-199 plus poster]. 6th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2003 Jun 24–28; Istanbul

Bonner J, Branson J, Milosavljev S, et al. Co-administration of lumiracoxib and warfarin does not alter the pharmacokinetic profile of R- or S-warfarin [abstract no. FRI0225]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 264CrossRef

Scott G, Rordorf C, Milosavljev S, et al. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis [abstract no. THU0233]. Ann Rheum Dis 2002; 61 Suppl. 1: 128. Plus poster presented at the Annual European Congress of Rheumatology; 2002 Jun 12–15; StockholmCrossRef

Hartmann S, Scott G, Rordorf C, et al. Lumiracoxib does not affect the pharmacokinetics of methotrexate in patients with stable rheumatoid arthritis [abstract no. P-193]. 6th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2003 Jun 24–28; Istanbul

10.

Wittenberg RH, Schell E, Krehan G, et al. Prospective, randomized study on the first-dose analgesic effect of lumiracoxib in osteoarthritis of the knee [abstract no. FRI0229]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 265

11.

Benevolenskaya L, Tuzun S, Hagin E, et al. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial [abstract no. FRI0246]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 270CrossRef

12.

Grifka J, Zacher J, Brown J, et al. Lumiracoxib is effective and well tolerated in patients with osteoarthritis of the hand: results from a randomized, placebo-controlled trial [abstract no. FRI0222]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 263

13.

Fleischmann R, Sheldon E, Maldonado Cocco J, et al. A prospective randomized 13-week study evaluating the efficacy of lumiracoxib in patients with osteoarthritis of the knee [abstract no. FRI0233]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 266

14.

Geusens P, Alten R, Rovensky J, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: results of a randomized double-blind study [abstract no. 544]. Arthritis Rheum 2003; 48 (9 Suppl.): 242

15.

Chan V, Clark A, Davis J, et al. A comparison of COX189, naproxen and placebo for relief of post-orthopedic surgery pain [abstract no. 951-P221 plus poster]. 10th World Congress on Pain; 2002 Aug 17–22; San Diego

16.

Davis J, Rhodes JR, Wolf R, et al. Lumiracoxib (Prexige) provides effective relief of postsurgical pain following total knee or hip arthroplasty [abstract plus poster]. 4th Congress of the European Federation of International Association for the Study of Pain Chapters; 2003 Sep 2–6; Prague

17.

Packman E, Packman B, Tseng L, et al. Lumiracoxib, a novel cox-2 selective inhibitor, is effective in the treatment of episodic tension-type headache [abstract no. 810]. J Pain 2004 Apr; 5 (31 Suppl. 1): 61

18.

Schell E, Boucher L, Tamasi L, et al. Long-term efficacy and tolerability of lumiracoxib in osteoarthritis of the knee [abstract no. FRI0224]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 264CrossRef

19.

Sloan V, Peterfy C, von Ingersleben G, et al. Fixed-flexion radiography of the knee suggests that lumiracoxib has no effect on articular cartilage in osteoarthritis [abstract no. 222]. 8th World Congress of the Osteoarthritis Research Society International; 2003 Oct 12–15; Berlin

20.

Hawkey CJ, Karateev D, Codreanu C, et al. Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189 compared with ibuprofen in osteoarthritis patients [abstract no. THU0226]. Ann Rheum Dis 2002; 61 Suppl. 1: 126

21.

Hawkey C, Hoexter G, Richard D, et al. Lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, has improved gastrointestinal safety and tolerability compared with non-selective nonsteroidal anti-inflammatory drugs: a pooled analysis [abstract no. 87]. Arthritis Rheum 2003 Sep; 48 (9 Suppl.): 79

22.

Hirschberg R, Della Casa Alberighi O, Hoexter G. Effect of lumiracoxib on blood pressure and fluid retention: a pooled analysis [abstract no. 123]. Rheumatology (Oxford) 2004 Apr; 43 Suppl. 2: ii66–7

23.

Novartis AG. Prexige is first COX-2 selective inhibitor to significantly reduce gastrointestinal events without compromising cardiovascular safety compared to NSAIDs [media release]. 2004 Aug 20

24.

Atherton C, Jones J, McKaig B, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004 Feb; 2(2): 113–20PubMedCrossRef

25.

Rordorf C, Kellett N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003 Sep 1; 18(5): 533–41PubMedCrossRef

26.

Mangold JB, Gu H, Rodriguez LC, et al. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004; 32(5): 566–71PubMedCrossRef

27.

Scott G, Yih L, Yeh CM, et al. Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects. J Clin Pharmacol 2004 Feb; 44(2): 193–9PubMedCrossRef

28.

Wilding IR, Connor AL, Carpenter P, et al. Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. Pharm Res 2004 Mar; 21(3): 443–6PubMedCrossRef

29.

Scott G, Reynolds CV, Milosavljev S, et al. Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. Clin Pharmacokinet 2004; 43(5): 341–8PubMedCrossRef

30.

Kalbag J, Elder C, Scott G, et al. Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. J Clin Pharmacol 2004 Jun; 44(6): 646–54PubMedCrossRef

31.

Scott G, Rordorf C, Reynolds C, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004; 43(7): 467–78PubMedCrossRef

32.

Kalbag J, Yeh C-M, Milosavljev S, et al. No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacol Res 2004 Aug; 50(2): 181–6PubMedCrossRef

33.

Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2004; 51(4): 549–57CrossRef

34.

Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis. Epub 2004 Feb 27

35.

Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21; 364(9435): 665–74PubMedCrossRef

36.

Zelenakas K, Fricke Jr JR, Jayawardene S, et al. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004 Mar; 58(3): 251–6PubMedCrossRef

37.

Kellstein D, Ott D, Jayawardene S, et al. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int J Clin Pract 2004 Mar; 58(3): 244–50PubMedCrossRef

38.

Bitner M, Kattenhorn J, Hatfield C, et al. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract 2004 Apr; 58(4): 340–5PubMedCrossRef

39.

Kivitz AJ, Nayiager S, Schimansky T, et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1189–98PubMedCrossRef

40.

Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug 21; 364(9435): 675–84PubMedCrossRef

41.

Hawkey CJ, Farkouh M, Gitton X, et al. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib: study design and patient demographics. Aliment Pharmacol Ther 2004 Jul 1; 20(1): 51–63PubMedCrossRef

42.

Novartis AG. Prexige (lumiracoxib), a novel COX-2 selective inhibitor approved in the United Kingdom [media release]. 2003 Sep 16

43.

First approval for Prexige: in Mexico. Scrip 2003 Apr 18; (2842): 23

44.

Prexige gains first EU approval in the UK. Scrip 2003 Sep 19; (2886): 19

Titel: Lumiracoxib
verfasst von: Katherine A. Lyseng-Williamson
Monique P. Curran
Publikationsdatum: 01.10.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 19/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464190-00008

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 19/2004

Lumiracoxib

Reactive Oxygen Species in the Cerebral Circulation

Prulifloxacin

Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease

Antiepileptic Drugs in the Treatment of Anxiety Disorders

Anidulafungin